Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
WHO Grade III Glioma: early-phase trial registry
8 of 12 indexed WHO Grade III Glioma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 8 currently recruiting · #1,429 of 28,707 conditions by registered trial count
WHO Grade III Glioma: 12 US clinical trials tracked, 8 recruiting.
WHO Grade III Glioma is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Nationwide Children's Hospital, running 3 of these trials.
Enrollment posture brief
Registry condition who-grade-iii-glioma
OPEN 8 | RECR 67% | LATE 0 | EARLY 8 | RANK #1429 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
WHO Grade III Glioma lists 8 open slots (67% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for WHO Grade III Glioma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
WHO Grade III Glioma is recruiting above its size-band peers.
8 of 12 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates WHO Grade III Glioma research.
Nationwide Children's Hospital accounts for 3 of 12 trials (25%). 7 distinct sponsors appear on at least one study for this condition label.
-
Typical WHO Grade III Glioma enrolment sits around 100 participants.
Median target enrolment is 100 among the 12 trials that report a genuine target (sentinel values excluded). 6 of those (50%) plan for fewer than 100 participants.
-
WHO Grade III Glioma research is mostly interventional.
11 interventional and 1 observational studies make up this index (91.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
Combination Therapy for the Treatment of Diffuse Midline Gliomas
University of California, San Francisco
NCT05009992
Targeted Pediatric High-Grade Glioma Therapy
Nationwide Children's Hospital
NCT05839379
Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma
Susan Chang
NCT04540107
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
NCT05843253
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
M.D. Anderson Cancer Center
NCT04479696
Study of Olutasidenib and Temozolomide in HGG
Rigel Pharmaceuticals
NCT06161974
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
M.D. Anderson Cancer Center
NCT04623931
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Nationwide Children's Hospital
NCT06333899
Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT03251027
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
University of California, San Francisco
NCT03749187
Mind-Body Intervention in Glioma Couples
M.D. Anderson Cancer Center
NCT03244995
Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma
City of Hope Medical Center
NCT03389230
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on WHO Grade III Glioma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on WHO Grade III Glioma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this WHO Grade III Glioma page
12 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 WHO Grade III Glioma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Nationwide Children's Hospital sponsors the most WHO Grade III Glioma trials on record, review their full trial history before evaluating a specific study. See Nationwide Children's Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This WHO Grade III Glioma condition card totals 12 registered trials; most-linked intervention Questionnaire Administration; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.